Does Rallies show 13F holders for RNA?

Yes. Rallies tracks hedge fund and 13F ownership data for RNA, including fund names, share counts, latest tracked quarter, and position changes when available.

Is RNA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RNA. It does not provide personalized investment advice.

RNA (Atrium Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Atrium Therapeutics, Inc. Common Stock (RNA) is a publicly traded Healthcare sector company. As of May 21, 2026, RNA trades at $13.12 with a market cap of $221.52M and a P/E ratio of -2.56. RNA moved -1.81% today. Year to date, RNA is -82.36%; over the trailing twelve months it is -57.91%. Its 52-week range spans $11.95 to $73.06. Analyst consensus is buy with an average price target of $25.00. Rallies surfaces RNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns RNA stock?

Hedge funds tracked by Rallies that own RNA include Soros Fund, Orbimed Advisors, Pentwater Capital, Sculptor Capital, and Farallon Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Atrium Therapeutics, Inc. Common Stock.

RNA Key Metrics

Key financial metrics for RNA
Metric	Value
Price	$13.12
Market Cap	$221.52M
P/E Ratio	-2.56
EPS	$-4.97
Dividend Yield	0.00%
52-Week High	$73.06
52-Week Low	$11.95
Volume	148.72K
Avg Volume	0
Revenue (TTM)	$18.75M
Net Income	$-684.63M
Gross Margin	0.00%

Top Hedge Funds Holding RNA

Soros Fund holds 840.98K shares of RNA, changed +0.00% as of Dec 31, 2025.
Orbimed Advisors holds 619.53K shares of RNA, changed -62.20% as of Dec 31, 2025.
Pentwater Capital holds 602.65K shares of RNA, changed -90.00% as of Mar 31, 2026.
Sculptor Capital holds 566.00K shares of RNA, changed +0.00% as of Dec 31, 2025.
Farallon Capital holds 349.36K shares of RNA, changed +0.00% as of Mar 31, 2026.

Latest RNA News

Atrium Therapeutics Posts $19.6M Q1 Revenue and Earns $15M BMS Milestone — May 14, 2026
Atrium Therapeutics Secures $15M Milestone, Opens $1.35B R&D and $825M Commercial Potential — Apr 23, 2026
Atrium Therapeutics Launches with $270M to Fund RNA Therapies for Rare Cardiomyopathies — Feb 27, 2026

Recent RNA Insider Trades

Hughes Steven George sold 2.02K (~$146.13K) on Jan 21, 2026.
Hughes Steven George sold 2.88K (~$208.51K) on Jan 21, 2026.
Boyce Sarah sold 6.39K (~$463.25K) on Jan 21, 2026.

RNA Analyst Consensus

2 analysts cover RNA: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $25.00.

Common questions about RNA

Who owns RNA stock?: Hedge funds tracked by Rallies that own RNA include Soros Fund, Orbimed Advisors, Pentwater Capital, Sculptor Capital, and Farallon Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Atrium Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for RNA?: Yes. Rallies tracks hedge fund and 13F ownership data for RNA, including fund names, share counts, latest tracked quarter, and position changes when available.
Is RNA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RNA. It does not provide personalized investment advice.